476 related articles for article (PubMed ID: 28708884)
1. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
[TBL] [Abstract][Full Text] [Related]
2. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
3. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
5. alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis.
Ha H; Lee JH; Kim HN; Kim HM; Kwak HB; Lee S; Kim HH; Lee ZH
J Immunol; 2006 Jan; 176(1):111-7. PubMed ID: 16365401
[TBL] [Abstract][Full Text] [Related]
6. Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.
Cong L; Zhang C; Tu G
Int J Clin Exp Pathol; 2015; 8(5):5988-96. PubMed ID: 26191332
[TBL] [Abstract][Full Text] [Related]
7. Aminothiazoles inhibit osteoclastogenesis and PGE
Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
[TBL] [Abstract][Full Text] [Related]
8. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
9. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
11. Magnolol Inhibits Osteoclast Differentiation via Suppression of RANKL Expression.
Hwang YH; Kim T; Kim R; Ha H
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004401
[TBL] [Abstract][Full Text] [Related]
12. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
14. Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis.
Horibe K; Nakamichi Y; Uehara S; Nakamura M; Koide M; Kobayashi Y; Takahashi N; Udagawa N
Immunology; 2013 Nov; 140(3):344-51. PubMed ID: 23826736
[TBL] [Abstract][Full Text] [Related]
15. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
16. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
17. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
18. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
19. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
20. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
